High affinity human antibodies to human cytomegalovirus (CMV) GB protein

US9688744B2 · kind B2 · utility

Assignee

• Trellis Bioscience, Inc. · US

Inventors

• Lawrence M. Kauvar · San Francisco, US
• Stote Ellsworth · Palo Alto, US
• William Usinger · Lafayette, US
• Krista McCutcheon · Burlingame, US
• Ying-Ping Jiang · Scotch Plains, US
• Fen Zhang · San Francisco, US
• Bo Chen · Jinan, CN
• Gizette Sperinde · El Granada, US
• Minha Park · Brisbane, US
• Orit Foord · Foster City, US

Key dates

• Filing date: Apr 27, 2015
• Grant date: Jun 27, 2017
• Expiry date: May 18, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.